Does Medicare Cover GLP-1 Medications?
Medicare is covering Wegovy, Zepbound and Foundayo for weight loss for the first time, through a program called the Medicare GLP-1 Bridge. The copay is $50 per month, flat, for eligible Part D enrollees. It started on July 1, 2026 and runs through December 31, 2027. Ozempic and Mounjaro remain covered under standard Part D for type 2 diabetes, as they have been.
Reviewed by GlobalGLP1 Editorial Team • Updated August 2026 • Sources: publicly available coverage data
Does Medicare cover GLP-1s for weight loss?
Yes, for now. A temporary program called the Medicare GLP-1 Bridge covers some of them for $50 a month.
It started on July 1, 2026 and is set to run until December 31, 2027. It runs in every state and in the US territories. You need Medicare drug coverage (Part D) to use it.
Outside this program, Medicare is not allowed to pay for medicine used for weight loss. That is the part people usually get caught out by.
Which medicines are covered
- Foundayo (tablet)
- Wegovy (injection or tablet)
- Zepbound (KwikPen only. Single dose Zepbound vials and pens are not covered.)
Who qualifies
You have to be 18 or older and meet one of these when you start:
- A BMI of 35 or higher
- A BMI of 30 or higher, plus at least one of these: a type of heart failure called diastolic heart failure, high blood pressure that is not under control, kidney disease at stage 3a or worse.
- A BMI of 27 or higher, plus at least one of these: prediabetes, a heart attack or stroke in the past, blocked arteries in your legs or arms that cause symptoms.
You are not eligible if:
- You already get a GLP-1 covered by your Medicare drug plan.
- You have type 2 diabetes, moderate to severe sleep apnea, or fatty liver disease. Your Part D plan may cover a GLP-1 for those instead, so ask about that route.
How to start
- Talk to your doctor or another health care provider. They send the prescription to the pharmacy and complete a prior authorization when it is requested.
- Your provider has to confirm you are taking the medicine alongside a diet and exercise program.
- The pharmacy may ask for your Medicare number or the last four digits of your Social Security number.
- You will get a letter in the mail confirming the medicine is covered under the Bridge.
Once approved, your prior authorization lasts through December 31, 2027. That covers refills and dose changes. It only restarts if you switch to a different GLP-1.
You need a prescriber who will write the prescription and handle the prior authorization. Find a GLP-1 clinic if you do not already have one.
What the $50 does not do
You pay $50 at the pharmacy for a one month supply. Depending on the drug that is either 28 or 30 days. A few things surprise people:
- The $50 does not count towards your yearly drug plan deductible or your out of pocket limit.
- It will not show up on your Part D Explanation of Benefits or on a Medicare Summary Notice.
- Extra Help cannot bring the $50 down.
- You cannot spread it across months with the Medicare Prescription Payment Plan.
Why it is temporary
Medicare is barred by law from paying for medicines used for weight loss. (Social Security Act sections 1860D-2(e)(2) and 1927(d)(2)) That rule has not changed. The Bridge works around it as a short term demonstration that runs outside normal Part D coverage, so it does not need the law changed to operate. CMS proposed removing the weight loss exclusion in November 2024 and then decided in April 2025 not to go ahead with it.
What happens when the Bridge ends on December 31, 2027 is not settled yet. A follow on program called BALANCE is not launching in Medicare in 2027. CMS says it extended the Bridge instead, and is using the extra time to collect data on how these medicines are used so it can share it with Part D plans ahead of possibly bringing BALANCE into Part D later.
Sources: Medicare.gov, Weight loss drugs, checked August 3, 2026; CMS, Medicare GLP-1 Bridge, page last updated July 13, 2026; CMS, Medicare GLP-1 Bridge FAQs, checked August 3, 2026. To check your own eligibility, go to Medicare.gov or call 1-800-MEDICARE (1-800-633-4227). TTY users can call 1-877-486-2048. This is general information, not medical or insurance advice.
Cite this page
GlobalGLP1.com. “Does Medicare cover GLP-1s for weight loss?” Accessed August 3, 2026. https://globalglp1.com/insurance/medicare
Free to quote with credit and a link back. If you need the underlying figures, our cost report and price transparency index publish downloadable data under CC-BY 4.0.
If your Medicare GLP-1 Bridge request is turned down
That is CMS's own wording. Unlike a Part D decision, a Bridge refusal cannot be appealed. What it can be is corrected and sent again.
What you do instead
Your prescriber can resubmit the prior authorization form, either because something was entered wrong the first time or because there is more to tell them. That is the route, and it is worth doing rather than treating the first answer as final.
- Decisions arrive within 72 hours. The decision is mailed to you and sent to your prescriber through the electronic prior authorization portal or by fax, within 72 hours of the request being submitted.
- You do not need a Part D refusal first. If your prescriber thinks you qualify, they can have the pharmacy send the claim straight to the Bridge.
If you were turned down because of another condition
Some people are turned down for the Bridge because Medicare already covers GLP-1s for their condition somewhere else. If any of these apply to you, you are not eligible for the Bridge, and your Part D plan is the route instead:
- Type 2 diabetes. Long covered by Part D.
- Moderate to severe obstructive sleep apnea. Covered by Part D for adults with obesity.
- Fatty liver disease with moderate to advanced scarring. Known formally as noncirrhotic MASH, and previously as NASH. Covered by Part D.
This matters because a Part D decision is not like a Bridge decision. Part D refusals do come with appeal rights, and your plan has to tell you in writing how to use them. Your plan's contact details are on your membership card.
Heart disease does not rule you out, but what the prescription is for does.
Wegovy is separately covered under Part D for lowering cardiovascular risk, so people with a cardiac history assume they are pushed down that route. Not quite. Unlike diabetes, sleep apnea and MASH, the Bridge prior authorization does not ask your doctor to certify that you have no established cardiovascular disease, so having it is not by itself a bar.
What matters is the reason the drug is prescribed. Your doctor has to certify on the Bridge form that it is for reducing excess weight and keeping it off. If it is being prescribed to lower your risk of a heart attack or stroke, CMS says that prescription should go to your Part D plan instead, and that holds even when weight loss is also a reason for it.
This is worth getting right before the form is submitted, because the two routes have different costs and only the Part D one can be appealed.
What helps on a resubmission
- Your BMI written down, and which of the three eligibility routes you meet.
- The qualifying condition for your route, if you are on the BMI 30 or BMI 27 path.
- Your prescriber's certification that the medicine is part of a diet and exercise program. The Bridge requires it.
- Anything that was missing or wrong the first time. That is what a resubmission is for.
Your prescriber submits it. If you do not have one, find a GLP-1 clinic.
Sources: CMS, Medicare GLP-1 Bridge FAQs for providers, checked August 3, 2026; Medicare.gov, Filing an appeal, checked August 3, 2026. The Bridge is a temporary federal program with its own rules. Part D, Medicaid, private insurance and TRICARE each handle refusals differently. This is general information, not medical, legal or insurance advice.
Medication Coverage
| Medication | Status | Tier | Notes |
|---|---|---|---|
| Ozempic (semaglutide) | Covered | Part D Formulary | Covered for type 2 diabetes under Medicare Part D. Not covered for weight loss under the bridge program. If you want semaglutide for weight loss, ask for Wegovy. |
| Wegovy (semaglutide) | Covered | GLP-1 Bridge ($50/mo) | Covered for weight loss starting July 1, 2026 via the Medicare GLP-1 Bridge at a flat $50/month copay. Requires prior authorization and BMI eligibility. Copay does not count toward your Part D deductible or annual out-of-pocket cap. |
| Mounjaro (tirzepatide) | Covered | Part D Formulary | Covered for type 2 diabetes under standard Part D. Not covered for weight loss under the bridge program. For weight-management tirzepatide coverage, ask for Zepbound. |
| Zepbound (tirzepatide) | Covered | GLP-1 Bridge ($50/mo) | Covered for weight loss starting July 1, 2026 via the Medicare GLP-1 Bridge (KwikPen formulation) at a flat $50/month copay. Same eligibility rules and copay structure as Wegovy under the bridge. |
| Foundayo (orforglipron) | Covered | GLP-1 Bridge ($50/mo) | Eli Lilly's daily weight-loss pill (FDA approved April 2026) covered under the Medicare GLP-1 Bridge starting July 1, 2026 at a flat $50/month copay. The first GLP-1 pill with no food, water, or time-of-day restrictions. |
| Saxenda (liraglutide) | Varies | Part D (limited) | Limited coverage on most Part D plans. Not included in the GLP-1 Bridge. Largely being replaced by newer medications. |
| Compounded semaglutide | Not Covered | N/A | Medicare does not cover compounded medications, including compounded semaglutide or tirzepatide. |
Prior Authorization
Prior authorization is required for all GLP-1 Bridge medications. Your prescribing provider submits the authorization request to your Part D plan on your behalf, attesting that you meet the BMI criteria and that the prescription is for weight reduction. Part D plans must respond within 72 hours for standard requests and 24 hours for urgent ones. Not every Part D plan is participating in the bridge, so confirm your plan is enrolled before scheduling your appointment.
Cost Estimates
Savings tip: The GLP-1 Bridge $50 copay does not count toward your Part D deductible or the $2,100 annual out-of-pocket cap, and it is not reduced by the Extra Help (Low Income Subsidy). For diabetes GLP-1s (Ozempic, Mounjaro) on standard Part D, the $2,100 annual cap does apply. Manufacturer savings cards cannot be used with any Medicare coverage.
Requirements for Coverage
- Active Medicare Part D enrollment (standalone PDP or Medicare Advantage with Part D)
- BMI 35 or higher automatically qualifies for the bridge program
- BMI 27 or higher with: pre-diabetes, previous heart attack, previous stroke, or symptomatic peripheral artery disease
- BMI 30 or higher with: heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease stage 3a+
- Prior authorization submitted by your prescribing provider
- Prescription must be specifically for weight reduction (not for diabetes or cardiovascular indications)
- Your prescriber must be enrolled in Medicare
Tips for Getting Approved
Schedule your appointment in May or June. Prior authorization takes time, and you want coverage from July 1, not a month after.
Confirm your Part D plan participates in the bridge before booking. Plan participation is voluntary. Call the number on your insurance card to ask.
Ask for Wegovy or Zepbound by name. Asking for Ozempic or Mounjaro for weight loss will result in a denial. The bridge covers the weight-management-approved products only.
Bring BMI documentation and any qualifying diagnosis records to your appointment. Your provider needs these for the prior authorization.
Low-income subsidy (Extra Help) recipients pay the full $50 copay under the bridge. The LIS discount does not apply to bridge program drugs.
The bridge runs through December 2027. After that, coverage may continue under the BALANCE model, but that is not guaranteed. Ask your plan about 2028 options closer to year-end 2027.
Approval Statistics
The GLP-1 Bridge has clearer eligibility criteria than prior weight-management coverage attempts, which should improve approval rates. Denials are most common when BMI documentation is missing or the prescription is coded for the wrong indication (diabetes vs. weight loss).
Common Denial Reasons & How to Avoid Them
How to avoid: Your provider needs a current BMI measurement in your chart and any qualifying diagnoses documented with the right codes. Bring your most recent lab results and get your BMI measured at the appointment.
How to avoid: The bridge only covers GLP-1s prescribed specifically for weight reduction. Make sure your provider codes the prior auth as an obesity or weight-management indication, not as a diabetes or cardiovascular treatment.
How to avoid: Not all Part D plans have enrolled in the bridge program. If your plan is not participating, your option is to switch plans during the next open enrollment period (October 15 through December 7), or call your plan to ask if they plan to join.
How to avoid: Ozempic and Mounjaro are not covered under the bridge. Only Wegovy, Zepbound, and Foundayo are. If your authorization was submitted for Ozempic for weight loss, resubmit it as Wegovy.
Step Therapy Requirements
Metformin is the standard first-line treatment. Most Part D plans require documented blood sugar (A1C) above 7% despite metformin before approving a GLP-1. Some plans may also require trying a sulfonylurea.
No step therapy requirement under the bridge program. You do not need to prove you tried other weight-loss medications first. Your provider documents that you meet the BMI and clinical criteria, and submits the prior authorization.
Frequently Asked Questions
Yes. Medicare Part D covers Ozempic and Mounjaro for type 2 diabetes with prior authorization. Starting July 1, 2026, the Medicare GLP-1 Bridge program covers Wegovy, Zepbound, and Foundayo for weight loss at a flat $50/month copay through December 31, 2027. Bridge eligibility requires BMI 35+ or BMI 27+ with pre-diabetes, prior heart attack, prior stroke, or peripheral artery disease. Compounded semaglutide is not covered. Manufacturer savings cards cannot be used with any Medicare coverage.
Medicare covers Ozempic (semaglutide) under Part D for type 2 diabetes, Mounjaro (tirzepatide) under Part D for type 2 diabetes, Wegovy (semaglutide) under the GLP-1 Bridge at $50/month for weight loss starting July 1, 2026, Zepbound (tirzepatide KwikPen) under the Bridge at $50/month, and Foundayo (Eli Lilly's daily orforglipron pill, FDA approved April 2026) also under the Bridge. Saxenda has limited Part D coverage on most plans. Compounded semaglutide is not covered. Note that not every Part D plan is participating in the Bridge, so confirm your plan is enrolled.
Yes. Medicare covers Wegovy for weight loss through the GLP-1 Bridge program at a flat $50 per month copay, from July 1, 2026 through December 31, 2027. You need Medicare Part D enrollment and you have to meet one of three BMI routes: a BMI of 35 or higher on its own; a BMI of 30 or higher with diastolic heart failure, uncontrolled high blood pressure, or stage 3a or worse kidney disease; or a BMI of 27 or higher with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease.
No. Ozempic is covered by Medicare Part D for type 2 diabetes, but not for weight loss. The GLP-1 Bridge covers weight-management-approved products: Wegovy, Zepbound, and Foundayo. If you want semaglutide for weight loss and have Medicare, ask your doctor about Wegovy.
The Medicare GLP-1 Bridge is a CMS demonstration program that covers Wegovy, Zepbound, and Foundayo for weight loss at a $50/month copay. It runs July 1, 2026 through December 31, 2027. Medicare is still barred by law from paying for medicine used for weight loss, so the Bridge operates outside normal Part D coverage rather than changing that rule. What replaces it after 2027 is not settled yet. A follow-on program called BALANCE is not launching in Medicare in 2027, and CMS says it extended the Bridge instead so it can collect data on how these medicines are used and share that with Part D plans ahead of possibly bringing BALANCE into Part D later.
Under the GLP-1 Bridge, the copay is $50 per month flat, regardless of dosage. Note that this $50 does not count toward your Part D deductible or the annual $2,100 out-of-pocket cap. Without the bridge, Wegovy runs $1,000 to $1,300 per month at retail.
Yes, through the GLP-1 Bridge, but only the KwikPen formulation. Single-dose Zepbound vials and pens are not covered. The copay is $50 a month and the eligibility rules are the same as for Wegovy: a BMI of 35 or higher on its own, a BMI of 30 or higher with certain heart, blood pressure or kidney conditions, or a BMI of 27 or higher with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease.
No. Federal law prohibits manufacturer savings cards from being used with Medicare, Medicaid, or other government-funded coverage. The $50 bridge copay and the $2,100 annual Part D out-of-pocket cap are the primary cost protections available.
The bridge is a temporary demonstration program running through December 2027. After that, coverage may continue through the BALANCE model or other CMS programs, but permanent statutory coverage requires Congress to change the law. Nothing is guaranteed past 2027.
No. The Extra Help (Low Income Subsidy) program does not apply to bridge program medications. You pay the full $50 regardless of income or subsidy status. This is one of the more counterintuitive aspects of the bridge program.
Find GLP-1 clinics near you
Coverage is only part of the answer. Most GLP-1 clinics charge cash rather than billing insurance, so what you actually pay varies a lot. Tell us your state and we will show you real options.
Explore More Resources
Find a GLP-1 Clinic That Takes Your Insurance
Search our directory of 3,318 clinics and filter by insurance, medication, and telehealth availability.
Disclaimer: Insurance coverage information is based on publicly available data and may not reflect your specific plan. Coverage, cost, and requirements can change. Always check with your insurer directly before making treatment decisions.